IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth

Don W. Coulter, Julie Blatt, A. Joseph D'Ercole, Billie M. Moats-Staats

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Neuroblastoma is the third most common solid tumor in children. Treatment continues to be challenging. The pathogenesis of neuroblastoma has been related to expression of the type 1 insulin-like growth factor receptor (IGF1R) and to transcription factor MYC-N amplification. Previous studies have shown that MYC-N expression is disrupted by blockade of the IGF1R with a specific monoclonal antibody, αIR3. Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin). Materials and Methods: BE-2(c) and IMR-32 neuroblastoma cell lines were treated with varying concentrations of αIR3, rapamycin and temsirolimus alone or in combination and the viable cells were counted. Results: Blockade of IGF1R signaling significantly inhibited cell growth as compared to untreated controls (p<0.05), and a combination of agents was more effective than each agent alone. Conclusion: The combination of rapamycin or temsirolimus with αIR3 blocks the IGF1R signaling pathway and has an antiproliferative effect on neuroblastoma cells warranting further investigations using inhibitors of IGF1R signaling as novel combination therapy for neuroblastoma.

Original languageEnglish (US)
Pages (from-to)1509-1516
Number of pages8
JournalAnticancer Research
Volume28
Issue number3 A
StatePublished - May 1 2008

Fingerprint

IGF Type 1 Receptor
Sirolimus
Neuroblastoma
Growth
Transcription Factors
Monoclonal Antibodies
temsirolimus
Cell Line
Therapeutics
Neoplasms

Keywords

  • IGF-I receptor
  • MYC-N
  • Neuroblastoma
  • Rapamycin
  • Temsirolimus
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. / Coulter, Don W.; Blatt, Julie; D'Ercole, A. Joseph; Moats-Staats, Billie M.

In: Anticancer Research, Vol. 28, No. 3 A, 01.05.2008, p. 1509-1516.

Research output: Contribution to journalArticle

Coulter, DW, Blatt, J, D'Ercole, AJ & Moats-Staats, BM 2008, 'IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth', Anticancer Research, vol. 28, no. 3 A, pp. 1509-1516.
Coulter, Don W. ; Blatt, Julie ; D'Ercole, A. Joseph ; Moats-Staats, Billie M. / IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. In: Anticancer Research. 2008 ; Vol. 28, No. 3 A. pp. 1509-1516.
@article{7cf4f540e20c4387bd2edb43b1239eb0,
title = "IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth",
abstract = "Background: Neuroblastoma is the third most common solid tumor in children. Treatment continues to be challenging. The pathogenesis of neuroblastoma has been related to expression of the type 1 insulin-like growth factor receptor (IGF1R) and to transcription factor MYC-N amplification. Previous studies have shown that MYC-N expression is disrupted by blockade of the IGF1R with a specific monoclonal antibody, αIR3. Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin). Materials and Methods: BE-2(c) and IMR-32 neuroblastoma cell lines were treated with varying concentrations of αIR3, rapamycin and temsirolimus alone or in combination and the viable cells were counted. Results: Blockade of IGF1R signaling significantly inhibited cell growth as compared to untreated controls (p<0.05), and a combination of agents was more effective than each agent alone. Conclusion: The combination of rapamycin or temsirolimus with αIR3 blocks the IGF1R signaling pathway and has an antiproliferative effect on neuroblastoma cells warranting further investigations using inhibitors of IGF1R signaling as novel combination therapy for neuroblastoma.",
keywords = "IGF-I receptor, MYC-N, Neuroblastoma, Rapamycin, Temsirolimus, mTOR",
author = "Coulter, {Don W.} and Julie Blatt and D'Ercole, {A. Joseph} and Moats-Staats, {Billie M.}",
year = "2008",
month = "5",
day = "1",
language = "English (US)",
volume = "28",
pages = "1509--1516",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth

AU - Coulter, Don W.

AU - Blatt, Julie

AU - D'Ercole, A. Joseph

AU - Moats-Staats, Billie M.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Background: Neuroblastoma is the third most common solid tumor in children. Treatment continues to be challenging. The pathogenesis of neuroblastoma has been related to expression of the type 1 insulin-like growth factor receptor (IGF1R) and to transcription factor MYC-N amplification. Previous studies have shown that MYC-N expression is disrupted by blockade of the IGF1R with a specific monoclonal antibody, αIR3. Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin). Materials and Methods: BE-2(c) and IMR-32 neuroblastoma cell lines were treated with varying concentrations of αIR3, rapamycin and temsirolimus alone or in combination and the viable cells were counted. Results: Blockade of IGF1R signaling significantly inhibited cell growth as compared to untreated controls (p<0.05), and a combination of agents was more effective than each agent alone. Conclusion: The combination of rapamycin or temsirolimus with αIR3 blocks the IGF1R signaling pathway and has an antiproliferative effect on neuroblastoma cells warranting further investigations using inhibitors of IGF1R signaling as novel combination therapy for neuroblastoma.

AB - Background: Neuroblastoma is the third most common solid tumor in children. Treatment continues to be challenging. The pathogenesis of neuroblastoma has been related to expression of the type 1 insulin-like growth factor receptor (IGF1R) and to transcription factor MYC-N amplification. Previous studies have shown that MYC-N expression is disrupted by blockade of the IGF1R with a specific monoclonal antibody, αIR3. Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin). Materials and Methods: BE-2(c) and IMR-32 neuroblastoma cell lines were treated with varying concentrations of αIR3, rapamycin and temsirolimus alone or in combination and the viable cells were counted. Results: Blockade of IGF1R signaling significantly inhibited cell growth as compared to untreated controls (p<0.05), and a combination of agents was more effective than each agent alone. Conclusion: The combination of rapamycin or temsirolimus with αIR3 blocks the IGF1R signaling pathway and has an antiproliferative effect on neuroblastoma cells warranting further investigations using inhibitors of IGF1R signaling as novel combination therapy for neuroblastoma.

KW - IGF-I receptor

KW - MYC-N

KW - Neuroblastoma

KW - Rapamycin

KW - Temsirolimus

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=45949109906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45949109906&partnerID=8YFLogxK

M3 - Article

C2 - 18630505

AN - SCOPUS:45949109906

VL - 28

SP - 1509

EP - 1516

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -